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Marrow- and Adipose Tissue-Derived
Mesenchymal Stem Cells Decline
With Increasing Donor Age
Jasmin Bagge 1,2, James N. MacLeod 2 and Lise C. Berg 1*
1Department of Veterinary Clinical Sciences, University of Copenhagen, Copenhagen, Denmark, 2Maxwell H. Gluck Equine
Research Center, Department of Veterinary Science, University of Kentucky, Lexington, KY, United States
Background: Bone marrow (BM)- and adipose tissue (AT)-derived mesenchymal stem
cells (MSCs) are used increasingly for autologous cell therapy in equine practice to
treat musculoskeletal and other injuries. Current recommendations often call for 10–100
million MSCs per treatment, necessitating the expansion of primary cells in culture prior
to therapeutic use. Of concern, human and rodent studies have shown a decline of
both MSC recovery from sampled tissue and in vitro proliferative capacity with increasing
donor age. This may be problematic for applications of autologous cell-based therapies
in the important equine demographic of older patients.
Objectives: To investigate the effect of donor age on the cellular proliferation of equine
BM- and AT-MSCs.
Study Design: In vitro study.
Methods: BM- and AT-MSCs and dermal fibroblasts (biological control) were harvested
from horses in five different age groups (n = 4, N = 60); newborn (0 days), yearling
(15–17 months), adult (5–8 years), middle-aged (12–18 years), and geriatric (≥22 years).
Proliferation of the cells was tested using an EdU incorporation assay and steady state
mRNA levels measured for targeted proliferation, aging, and senescence biomarkers.
Results: The cellular proliferation of equine BM- and AT-MSCs declined significantly in
the geriatric cohort relative to the younger age groups. Proliferation levels in the two MSC
types were equally affected by donor age. Analysis of steady state mRNA levels showed
an up-regulation in tumor suppressors, apoptotic genes, and multiple growth factors in
MSCs from old horses, and a down-regulation of some pro-cycling genes with a few
differences between cell types.
Main Limitations: Potential age-dependent differences in cell function parameters
relevant to cell-therapy application were not investigated.
Conclusions: The cellular proliferation of equine BM- and AT-MSCs declined at
advanced donor ages. High levels of in vitro proliferation were observed in both MSC
types from horses in the age groups below 18 years of age.
Keywords: horse, aging, donor age, mesenchymal stem cells, proliferation, tumor suppressors
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INTRODUCTION
Mesenchymal stem cells (MSCs) have shown potential to
facilitate the repair of certain musculoskeletal and other tissue
injuries, and are being used increasingly in equine practice (1–3).
Cellular proliferation has been shown to be positively correlated
with regenerative potential (4). Bone marrow (BM)- and adipose
tissue (AT)-derived MSCs are currently the choice of therapy,
where BM-MSCs have shown higher potential to treat cartilage
and bone injuries (5, 6). For successful therapies, a substantial
number of cells are needed, which often requires extensive ex
vivo cell expansion prior to implantation. Generally, cell-based
therapy protocols call for 10–100 million MSCs per treatment
and are typically used for clinical applications at passage 3–
4 (7–10). Additionally, repeated MSC applications have shown
beneficial effects in vivo, which further increases the need for
cells (11).
Unfortunately, human and rodent studies have shown both
a decline in recovery from sampled tissues and a drop in
the in vitro proliferative capacity of BM- and AT-MSCs with
increasing donor age (12–15). The frequency of BM-MSCs
is lower compared to AT-MSCs at isolation (16, 17). MSCs
from aged donors have also been determined to have increased
expression of cell cycle arrest genes like p53 and p21 (12, 14,
18), and decreased expression of growth factors like vascular
endothelial growth factor (VEGF) and insulin-like growth factor
(IGF) (13).
Very little is known about these age-dependent relationships
in horses. No equine BM-MSC donor age-dependent
studies have been reported with multiple age groups to
provide thresholds relevant for clinical practice, or have
investigated if different MSC types are equally affected by
donor age (16, 18–20). Expansion of cell numbers invariably
causes a treatment delay, which may be an issue for some
applications where early treatment has been shown to be
beneficial (21). The inability to even achieve cell numbers
recommended for therapy would likely have a far greater impact.
Together, this may limit the clinical potential of MSCs from
aged horses.
Presently, autologous treatment is preferred over allogenic
treatment due to the risk of immunological reactions associated
with allogenic treatments in equine models (22, 23). Clinical
issues that may benefit from cell-based therapies occur
across the full range of equine ages, including orthopedic
problems in older sport and recreational horses (24).
Together, this emphasizes the significance of understanding
the effect donor age has on the proliferative capacity of
equine MSCs.
The current study was, therefore, designed to test the
hypothesis that increasing donor age is a major variable
impacting equine BM- and AT-MSC proliferation with
decreasing capacities. The aim of this study was to compare
cellular proliferation and the expression of genes known to
regulate cell proliferation in BM- and AT-MSCs from horses in
five different age groups, and to test if the two MSC types were
equally affected by donor age.
MATERIALS AND METHODS
Experimental Samples
Three different cell types, BM-MSCs, AT-MSCs, and dermal
fibroblasts (DF) (biological non-stem cell control), were
harvested as detailed below immediately post-mortem from
horses of mixed breeds across five age groups. Four donor horses
were used for each cell type and age group. The age groups were
newborn (0 days old), yearling (15–17-month old), adult (5–8-
year old), middle-aged (12–18-year old), and geriatric (≥22-year
old). DFs were chosen as a biological control due to their
morphology and to have a non-stem cell type for comparison to
potential MSC age-related changes. All horses were euthanized
due to reasons unrelated to the current study. No systemic
illness was apparent in any of the subjects, with the exception of
some old horses as noted (Table 1). The study was conducted
according to the ethical guidelines of animal research at the
University of Copenhagen and the University of Kentucky. A
written informed consent was obtained from all privately-owned
horses prior to sample collection. Sample size was determined
by two-sample t-test power analysis in R (version 3.6.0, The R
Foundation for Statistical Computing, Vienna, Austria) using
MSC proliferation pilot data (not shown) from newborn and
geriatric horses. The power was set to 0.80 and the minimum
relevant difference in proliferation rate was set to 10% between
study groups. Experiments were performed at two different
universities. An inter-laboratory control of BM-MSCs from the
same yearling cell line was tested for proliferation rate and steady
state mRNA levels at both sites after shipping RNA on dry-ice
from one laboratory to the other to perform gene expression
analyses on the same machines. No indication of significant
differences between laboratories was found (data not shown).
Plasticware, culture medium, reagents, commercially available
kits, and protocols were kept constant throughout the entire
study for all samples.
Bone Marrow Derived MSC Collection and
Isolation
BMwas collected immediately post-mortem from the sternum of
12 female and 8 male horses (Table 1).
For newborns, BM was collected as described by Vidal
et al. (16) with a few modifications. Briefly, BM samples
were obtained from the 4th−6th sternebrae by sterile curettage
after splitting the sternum along the midline. The marrow
trabecular bone was transported on ice to the laboratory in sterile
Dulbecco’s phosphate buffered saline (dPBS, Thermo Fisher
Scientific, Waltham, MA, USA) with 2% (v/v) amphotericin B
(Thermo Fisher Scientific, Waltham, MA, USA) and 2% (v/v)
penicillin/streptomycin (P/S, Thermo Fisher Scientific,Waltham,
MA, USA) (isolation solution) and processed within 2 h of
collection. Marrow trabecular bone was rinsed twice in 37◦C
isolation solution and crushed before being grown as explant
culture in two T75 flasks (Cellstar BioGreiner tissue culture
treated flasks, Sigma-Aldrich, St. Louis, MI, USA) with 12
mL/flask Dulbecco’s modified Eagle’s medium (Gibco DMEM,
1 g/L glucose, with phenol red, GlutaMAX, and pyruvate,
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TABLE 1 | Overview of biological replicates used as study population.
Age group Age Breed Gender BM-MSCs AT-MSCs DFs Reason for euthanasia
Newborn 0 d. Pony M Yes Yes Yes Research
0 d. Pony M Yes Yes Yes Research
0 d. Pony M Yes Yes Yes Research
0 d. Pony F Yes Yes Yes Research
Yearling 15 mo. Mixed, light breed M Yes No Yes Research
15 mo. Mixed, light breed M No Yes Yes Research
15.5 mo. Mixed, light breed M Yes No No Research
16 mo. Mixed, light breed F Yes Yes Yes Research
16 mo. Mixed, light breed F Yes Yes Yes Research
16 mo. Mixed, light breed M No Yes No Research
Adult 5 yo. Standardbred F Yes Yes No Research
5 yo. Standardbred F No No Yes Research
6 yo. Standardbred F No No Yes Research
6 yo. Standardbred F No No Yes Research
7 yo. Standardbred F Yes Yes No Research
7 yo. Standardbred M Yes Yes Yes Research
8 yo. Warmblood M Yes Yes No Unknown
Middle-aged 12 yo. Standardbred F No No Yes Research
12 yo. Standardbred F No No Yes Research
13 yo. Standardbred F Yes Yes No Research
14 yo. Pony M No Yes No Unknown
15 yo. Standardbred F No Yes No Research
15 yo. Standardbred F Yes No No Research
16 yo. Pony M No Yes No Unknown
16 yo. Thoroughbred F Yes No Yes Research
18 yo. Thoroughbred F Yes No Yes Weight loss
Geriatric 22 yo. Thoroughbred F Yes Yes Yes Research
25 yo. Coldblood M Yes Yes No Unknown
25 yo. Thoroughbred F Yes Yes Yes Lymphoma
31 yo. Thoroughbred F Yes Yes Yes Colic
32 yo. Thoroughbred F No No Yes Research
*Research horses were euthanized for reasons unrelated to the current study and all were in apparent good health at the time of sacrifice. d., days old; mo., months old; yo., years old;
M, male; F, female; BM, bone marrow; AT, adipose tissue; MSCs, mesenchymal stem cells; DF, dermal fibroblasts.
Thermo Fisher Scientific, Waltham, MA, USA), 10% (v/v) fetal
bovine serum (FBS, Thermo Fisher Scientific, Waltham, MA,
USA), 1% (v/v) P/S, and 1% (v/v) amphotericin B (isolation
medium). After 48 h, BM crusts and non-adherent cells were
aspirated along with the isolation medium, and the medium was
changed to expansion medium containing DMEM, 10% FBS,
and 1% P/S.
For the four older age groups, 20mL of BM aspirate was
collected from the 4th−6th sternebrae with a 11G Jamshidi R©
BM needle (Henry Schein Vet, Dublin, OH, USA) and BM-MSCs
were isolated with Ficoll-Paque R© PREMIUM (GE Healthcare,
Chicago, IL, USA) as previously described (16, 25).
The method used for sample collection of BM-MSCs varied
between newborns and the other age groups because the
smaller size and cartilaginous sternum of newborn foals proved
challenging for the accurate positioning of Jamshidi R© needles to
obtain high quality bone marrow aspirates.
Adipose Tissue Derived MSC Collection
and Isolation
AT was collected and isolated from the gluteal region above the
biceps femoris muscle next to the tail base of 10 female and 10
male horses (Table 1) as previously described (25).
Briefly, the gluteal area next to the tail base was surgically
clipped and prepared, and 10 grams of AT was collected through
a ∼8 × 8 cm surgical window. AT was transferred to a 50mL
polypropylene tube (Falcon) with ice cold isolation solution and
transported on ice to the laboratory, where the tissue was further
processed within 2 h of collection. AT was washed two times
in isolation solution and dissected into smaller pieces where
visible blood vessels were removed. AT was digested in sterile
filtered (0.2µm) enzyme medium consisting of DMEM (1 g/L
glucose), 1% (v/v) P/S, 50µg/mL gentamycin (Sigma-Aldrich,
St. Louis, MI, USA), and 1 mg/mL collagenase type I (Thermo
Fisher Scientific, Waltham, MA, USA) for 3 h at 37◦C and 30
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rpm. Released cells were filtered through a 70µm cell strainer,
washed twice in sterile dPBS, and centrifuged at 500 g for 5min
between the washes. The pellet was then re-suspended in 24mL
isolation medium supplemented with 50µg/mL gentamycin and
distributed into two T75 flasks. Medium change to expansion
medium occurred 48 h after isolation.
Dermal Fibroblast Collection and Isolation
Unfortunately, DFs had not been collected originally from all
donor horses for which archived primary BM and AT cell lines
were available. To include this biological control cell type in
the experimental design of the current study, additional donors
were recruited in the appropriate age group as needed. DFs were
harvested and isolated from the gluteal region above the biceps
femorismuscle next to the tail base of 14 female and 6male horses
(Table 1) as previously described (6).
In short, approximately 6 grams of dermal tissue was collected
from either the same surgical window generated to collect AT-
MSCs or one comparably positioned. Dermis was transferred
to a 50mL polypropylene tube (Falcon) with ice cold isolation
solution and transported on ice to the laboratory where the
tissue was further processed within 2 h of collection. The dermal
tissue was washed two times in isolation solution, dissected into
smaller pieces, and digested in sterile filtered (0.2µm) enzyme
medium consisting of dPBS, 1% (v/v) P/S, 1% (w/v) bovine serum
albumin (BSA, Sigma-Aldrich, St. Louis, MI, USA), 50µg/mL
gentamycin, and 1 mg/mL collagenase type I for 2 h at 37◦C and
30 rpm. Released cells were filtered through a 70µm cell strainer,
washed twice in sterile dPBS, and centrifuged at 1,000 g for 4min
between the washes. The pellet was then re-suspended in 24mL
isolation medium supplemented with 50µg/mL gentamycin and
distributed into two T75 flasks and grown at 37◦C in air with
5% CO2. A culture medium change to expansion medium was
performed 48 h after isolation.
Cell Expansion and Storage
The cells were cultured in expansion medium at 37◦C in a
humidified atmosphere containing 5% CO2. Expansion medium
was changed every 2–3 days. At approximately 80% confluence,
the cells were passaged with Trypsin/EDTA (Thermo Fisher
Scientific, Waltham, MA, USA). Cell counting was performed
manually using trypan blue (Thermo Fisher Scientific, Waltham,
MA, USA) and a hemocytometer. The cells were grown with
a seeding density of 500,000 cells per T75 flask. At passage 2,
the cells were cryopreserved at a concentration of 2–3 million
cells/mL freezing medium (Recovery-Cell Culture Freezing
Medium R©, Thermo Fisher Scientific, Waltham, MA, USA) in
cryogenic vials (Nalgene, Thermo Fisher Scientific, Waltham,
MA, USA).
For subsequent experimental applications, the cells were
thawed in 37◦C expansion medium and washed three times
in dPBS before being plated and grown in expansion medium.
As before, the cells were incubated at 37◦C and 5% CO2
with a medium change every 2–3 days. Proliferation and gene
expression analyses were conducted with passage 4 cells.
Assessment of Cellular Proliferation
Cellular proliferation was quantified by determining levels
of incorporated 5-ethynyl-2′-deoxyuridine (EdU) after pulse
labeling using a Click-iT Plus Alexa Fluor 594 EdU Imaging Kit R©
(Thermo Fisher Scientific, Waltham, MA, USA) as described
previously (19).
In short, passage 4 cells were seeded at a density of 25,000 cells
per well in a 24-well plate (Thermo Fisher Scientific, Waltham,
MA, USA) and cultured in expansion medium for 48 h. The
cells were then pulsed for 24 h with 8µM EdU (Jena Bioscience,
Jena, Germany). A total of eight technical replicate wells were
pulsed with EdU, and one control well was kept under normal
expansion medium without pulsing. Next, the cells were fixed in
4% methanol-free paraformaldehyde (Thermo Fisher Scientific,
Waltham, MA, USA) and washed with 3% (w/v) BSA (Sigma-
Aldrich, St. Louis, MI, USA) before being permeabilized with
0.1% Triton-X (Sigma-Aldrich, St. Louis, MI, USA). For EdU
label detection, the cells were incubated for 30min with the kit
reagent cocktail containing Alexa 594. The staining cocktail was
removed and the cells were washed with 3% BSA and dPBS
before being counterstained with 4′,6-diamidino-2-phenylindole
dihydrochloride (DAPI, Thermo Fisher Scientific,Waltham,MA,
USA) for 15min at a concentration of 1µg/mL. The fluorophore
staining cocktail was prepared fresh for each assay and the
cells were incubated while protected from light. Images of the
cells were taken in the dark using a fluorescence microscope
with DAPI and Alexa 594 filters. A total of three random
images were taken per well for each fluorophore. The total
number of cell nuclei and the number of proliferating cells were
counted using automated imaging software (Image-J version
1.48, NIH, Bethesda, MD, USA). The cellular proliferation rate
was calculated as the number of EdU labeled nuclei as a
percentage of total cell nuclei in each image. The proliferation
percentage was calculated for all three images per well and
then averaged.
Differential Gene Expression
RNA Isolation and Reverse Transcription
Passage 4 cells were expanded in T75 flasks with expansion
medium. At approximately 80% confluence, the cells were
extracted with QIAzol R© (Qiagen, Germantown, MD, USA)
and snap frozen in liquid nitrogen before being stored at
−80◦C prior to RNA isolation. The cells were homogenized
with a PowerGen 125 homogenizer (Thermo Fisher Scientific,
Waltham, MA, USA). Total RNA was isolated using a Qiagen
RNeasy Mini Kit R© (Qiagen, Germantown, MD, USA) with
modifications as previously described (26). RNA quantity
was estimated with a NanoDrop spectrophotometer (Thermo
Fisher Scientific, Waltham, MA, USA) prior to ethanol
precipitation. Purified RNA was quantified using a Qubit BR
Assay (Thermo Fisher Scientific, Waltham, MA, USA) and
NanoDrop spectrophotometer. The quality of the purified RNA
was assessed with a Bioanalyzer 2100 (Eukaryotic Total RNA
Nano & Pico Series II, Agilent Technologies, Santa Clara, CA,
USA). All purified RNA samples met the following quality
thresholds; 260/280 ratios of 1.9–2.1, 260/230 ratios of 1.8–2.28,
and an Agilent RNA integrity number (RIN) of ≥8.0, with the
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exception of one sample (RIN = 7.5) that behaved as expected
in down-stream analyses and thus was not excluded from the
study. Removal of potential genomic DNA contamination and
reverse transcription of total RNA to cDNA was achieved using
a commercially available kit as per manufacturer’s protocol
(Maxima First Strand cDNA Synthesis Kit R© for RT-qPCR with
dsDNase, Thermo Fisher Scientific, Waltham, MA, USA). All
cDNA samples were diluted with nuclease-free water to 13.9
ng/uL and stored at−80◦C.
Real-Time Quantitative PCR
Forty seven biomarkers were selected for gene expression
analyses based on functional annotation. Selected gene loci
were chosen due to important biological relevance for cell
proliferation, cellular senescence, or evidence of age-dependent
variation related to proliferation in the literature. Commercially
available, validated equine-specific TaqMan R© primer-probe sets
(Thermo Fisher Scientific, Waltham, MA, USA) (Table 2) for
all biomarkers were used to quantitate steady state mRNA
levels. The functionality of all primer-probe sets was tested
against a positive control equine sample containing mixed cDNA
from equal amounts of a 43-sample pool of various tissues
(27), day 35 whole fetus, and neonatal epiphyseal cartilage.
Negative controls of RNase-free water and minus-template were
incorporated, and each sample was run in duplicate. Real-
time quantitative PCR (RT-qPCR) reactions were conducted
in a 384-well plate with 62.55 ng cDNA per reaction using
a robotic ViiATM RT-qPCR System (Thermo Fisher Scientific,
Waltham, MA, USA). LinRegPCR was used to measure reaction
amplification efficiencies and cycle threshold (Ct) values were
calculated (28). All targets yielded amplification efficiencies
close to 2 except for the negative controls that showed no
amplification as expected. Three commercially available equine-
specific endogenous control TaqMan R© primer-probe sets; β-2-
microglobulin (B2M), β-glucoronidase (GUSB), and ribosomal
protein lateral stalk subunit P0 (RPLP0), were tested against
all samples. Using NormFinder software (Aarhus University
Hospital, Aarhus, Denmark) (29), GUSB was determined as
having the most uniform performance across all cell types and
age groups.
Steady state mRNA levels from the selected gene loci were
determined by RT-qPCR using the BIOMARK HD System
(Fluidigm Corporations, South San Francisco, CA, USA) as
previously described (30) at a cDNA concentration of 13.9 ng/µL.
Negative controls and seven dilutions of the positive control
sample described above were incorporated, each dilution being 3-
fold and ranging from 0.17 to 125 ng/µL. The Fluidigm protocol
was carried out using the 96.96 Dynamic Array (Fluidigm
Corporations, South San Francisco, CA, USA) according to
manufacturer’s instructions. Data were analyzed with Fluidigm
Real-Time PCR Analysis Software in the BIOMARK instrument
(Fluidigm Corporations, South San Francisco, CA, USA), where
Ct values were calculated. Delta Ct values were determined for
each sample by subtracting the corresponding Ct value of the
endogenous control (GUSB). The positive control was used as
a calibrator to calculate 11Ct values. Relative expression (RQ)
of the gene targets were calculated using the 2−11Ct method
(31). RQ levels were used for graphical bar/boxplot presentations
made in GraphPad Prism (version 8.0.1, GraphPad Prism, San
Diego, CA, USA), and Ln(RQ) values were used for heatmap and
statistical analyses (Supplementary Table 1).
For visualization of relative transcript levels between
experimental groups, a heatmap was generated from the
averaged Ln(RQ) levels, grouping the samples according to cell
type and donor age, and genes according to biological function.
The heatmap was prepared in R (version 3.6.0, The R Foundation
for Statistical Computing, Vienna, Austria) using the heatmap
ggplot function.
Statistical Analysis
The cellular proliferation data, comparing age groups within cell
types and across cell types, were analyzed with a generalized
linear mixed model using The GLIMMIX Procedure in SAS
(version 9.4, SAS Institute Inc., Cary, NC, USA) with Tukey-
Kramer’s post hoc modifications for multiple comparisons. Gene
expression data were analyzed in two steps. Initially, one-way
analysis of variance (ANOVA) using SAS (version 9.4, SAS
Institute Inc., Cary, NC, USA) was applied individually to all
47 gene targets within each cell type to look for donor age
effects. Next, transcripts demonstrating significant differences
by ANOVA and more than 5-fold difference between study
groups on the heatmap were analyzed using The GLIMMIX
Procedure with Tukey-Kramer’s post hoc modifications for
multiple comparisons to compare across tissue types. Normality
of data was confirmed by QQ-plots and Shapiro-Wilk test.
Statistical analyses of Fluidigm RT-qPCR results were performed
on individual extracted Ln(RQ) values. Genes with missing data
points (due to lack of detectable expression) were removed from
the statistical analysis for the given cell type. To control for non-
paired samples and potential inter-laboratory variables, horse
number and laboratory were added to the statistical models as
additional factors. Data were considered statistically significant
at p < 0.05.
RESULTS
EdU Proliferation Assay
All cell lines were able to be expanded to ∼80% confluence at
passage 4. When assessing the effect of donor age within one
cell type, there was a significant decrease in cellular proliferation
with increasing donor age for BM-MSCs (p = 0.02), AT-MSCs
(p = 0.0003), and DFs (p < 0.0001) (Figure 1). Interestingly,
there was no significant difference in pairwise comparisons
between age groups other than geriatric horses for BM- and
AT-MSCs (Figure 1). Representative images of proliferating BM-
MSCs from horses in different age groups are shown in Figure 2.
All cell types were equally affected by donor age (p =
0.3) and no significant differences were observed in cellular
proliferation between BM- and AT-MSCs in any age group (p >
0.4) (Figure 3). When comparing cell types independent of age
groups, DFs had a higher overall level of cellular proliferation
relative to BM-MSCs (p = 0.006) and AT-MSCs (p = 0.02).
No Alexa 594 background staining was detected in any of the
negative control wells grown without EdU pulsing. No study
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TABLE 2 | Overview of TaqMan primer-probe sets used in RT-qPCR reactions.
Gene ID Gene name(s) Gene function* ThermoFisher Assay ID
ABI3BP ABI family member 3 binding protein Decrease proliferation Ec06625599_m1
AQP1 Aquaporin Increase proliferation Ec06625425_m1
AREG Amphiregulin Mitogenic effect Ec06992855_m1
BARD1 BRCA1-associated RING domain 1 Tumor suppressor Ec07061151_m1
BAX BCL2 associated X apoptosis regulator Pro-apoptotic Ec07016716_s1
BCL2 B-cell lymphoma 2 Anti-apoptotic Ec07005800_g1
BMP3 Bone morphogenic factor 3 Increase proliferation Ec07037656_m1
BRCA1 Breast cancer type 1 Tumor suppressor Ec07017862_s1
CASP3 Caspase 3 Apoptotic gene Ec03470391_m1
CASP8 Caspase 8 Apoptotic gene Ec06959413_m1
CAVIN1 Caveolae associated protein 1 Induce senescence Ec07036873_m1
CCND1 Cyclin D1 Pro-cycling gene Ec07036996_m1
CDKN1A p21, Cyclin-dependent kinase inhibitor 1A Tumor suppressor Ec06955195_m1
CLU Clusterin Anti-apoptotic Ec03468575_m1
COMP Cartilage oligomeric matrix protein Increase proliferation Ec03468062_m1
CSF2 Colony stimulating factor 2 Increase proliferation Ec03468208_m1
CTGF Connective tissue growth factor Increase proliferation Ec06625777_gH
CTNNB1 Beta-catenin Increase proliferation Ec00991819_m1
EPGN Epithelial mitogen Mitogen Ec06992859_m1
FGF1 Fibroblast growth factor 1 Mitogen Ec01092738_m1
FGF5 Fibroblast growth factor 5 Mitogen Ec04656774_m1
FGF18 Fibroblast growth factor 18 Mitogen Ec03248217_g1
GDF6 Growth differentiation factor 6 Tumor suppressor Ec07097112_m1
GLB1 Beta-galactosidase Senescence marker Ec06954363_m1
GLI3 GLI family zinc finger 3 Regulate proliferation Ec06625512_m1
HDGF Hepatoma-derived growth factor Mitogen Ec07037751_m1
HGF Hepatocyte growth factor Mitogen Ec07000054_m1
IGF1 Insulin-like growth factor 1 Mitogen Ec03468689_m1
IGFBP5 Insulin-like growth factor binding protein 5 Mitogen binding Ec03470296_m1
LOC100146270 p16, Cyclin-dependent kinase 4 inhibitor B Senescence marker Ec07037471_mH
MET MET proto-oncogene, receptor tyrosine kinase Regulate proliferation Ec02622441_m1
MYC c-myc Pro-cycling Ec07007511_m1
PCNA Proliferating cell nuclear antigen Increase DNA replication Ec06974312_m1
PDGFD Platelet-derived growth factor subunit D Mitogen Ec06997714_m1
PHB Prohibitin Inhibits DNA synthesis Ec07055990_m1
PTCH2 Patched 2 Tumor suppressor Ec06625424_g1
S100A1 S100 calcium binding protein A1 Inhibits proliferation Ec03470173_g1
SNAI2 Snail family transcriptional repressor 2 Anti-apoptotic Ec06625397_m1
SOST Scherostin Pro-apoptotic Ec07036868_m1
TERT Telomerase reverse transcriptase Subunit of telomerase Ec06972692_m1
TGFA Transforming growth factor alpha Regulate proliferation Ec06949183_m1
TGFB1 Transforming growth factor beta 1 Regulate proliferation Ec06625477_m1
TGFB2 Transforming growth factor beta 2 Regulate proliferation Ec07074189_g1
TGFB3 Transforming growth factor beta 3 Regulate proliferation Ec00682163_m1
TIMP2 Metallopeptidase inhibitor 2 Decrease proliferation Ec03470558_m1
TP53 Tumor protein 53 Tumor suppressor Ec03470648_m1
VEGFA Vascular endothelial growth factor A Mitogen Ec03467879_m1
B2M Beta-2-microblobulin Endogenous control Ec03468699_m1
GUSB Beta-glucoronidase Endogenous control Ec03470630_m1
RPLP0 Ribosomal protein lateral stalk subunit P0 Endogenous control Ec04947733_g1
*NIH, Genetics Home Reference (https://ghr.nlm.nih.gov/gene/).
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FIGURE 1 | Age-dependent changes in cellular proliferation within each cell type. Box plots showing the cellular proliferation in percentage of bone marrow (BM)- and
adipose tissue (AT)-derived mesenchymal stem cells (MSC) and dermal fibroblasts (DF) from horses in five different age groups (n = 4, N = 60) after 24 h of labeling
with 8µM EdU. Age groups within the same cell type not labeled with the same letter are significantly different from each other (p < 0.05). d., days old; mo., months
old; yo., years old.
group reached a cellular proliferation of 100% (Figure 1). Alexa
594 staining was detected in all wells pulsed with EdU, together
with DAPI staining.
Gene Expression
Out of the 47 targeted gene loci related to proliferation and aging,
steady state mRNA levels were affected by donor age in four
biomarkers (9%) for AT-MSCs, 17 biomarkers (36%) for BM-
MSCs, and 15 biomarkers (32%) for DFs. Differentially expressed
genes as a function of donor age are shown in Table 3 and in a
Venn-diagram in Figure 4 where intersections are visualized.
Multiple growth factors (FGF1, FGF18, GDF6, PDGFD,
TGFA, and VEGFA) were up-regulated in BM-MSCs from old
horses compared to young horses. On the other hand, fibroblast
growth factor 5 (FGF5) was found at lower levels in BM-MSCs
from geriatric horses compared to newborns (p = 0.02), and
in higher levels in AT-MSCs compared to BM-MSCs (p =
0.008). Cell cycle regulators cyclin D (CCND1) and proliferating
cell nuclear antigen (PCNA) were not significantly affected by
donor age in either of the two stem cell types, but were down-
regulated in DFs from geriatric horses (p = 0.01 and p < 0.0001,
respectively). In general, cyclin D was found at higher levels in
BM-MSCs compared to AT-MSCs and DFs (p < 0.003), whereas
PCNA was found at higher levels in DFs compared to AT-MSCs
(p < 0.0001) and BM-MSCs (p= 0.0004). For positive regulators
of cell proliferation colony stimulating factor 2 (CSF2) was up-
regulated in BM-MSCs from geriatric horses compared to all
other age groups (p < 0.0005), whereas GLI family zinc finger
3 (GLI3) was down-regulated in geriatric BM-MSCs (p ≤ 0.02)
(Figure 5, Table 3).
For BM-MSCs, expression of the senescence marker
β-galactosidase (GLB1) was significantly higher in geriatric
horses compared to newborns (p = 0.002), yearlings (p = 0.02),
and adult horses (p = 0.03), and in middle-aged compared to
newborn horses (p = 0.01). GLB1 was not significantly affected
by donor age in AT-MSCs or DFs. Higher GLB1 expression was
seen in BM-MSCs compared to AT-MSCs and DFs in geriatric
horses (p = 0.001 and p = 0.0003, respectively) (Figure 5,
Table 3). Steady state mRNA levels of aquaporin (AQP1), which
encodes a membrane-associated water channel protein, were
low relative to the positive control sample and changed as a
function of age in all three cell types, increasing in older horses
for BM-MSCs and DFs while decreasing in AT-MSCs.
As shown in Figure 6, the tumor suppressors p16
(LOC100146270) and p21 (CDKN1A) were both up-regulated
in geriatric BM-MSCs compared to newborn horses (p = 0.01
and p = 0.02, respectively). Moreover, p16 and p21 showed
higher levels in BM-MSCs than in AT-MSCs (p ≤ 0.02) or DFs
(p ≤ 0.0002). For AT-MSCs, the tumor suppressor p53 (TP53)
had higher expression in geriatric horses compared to newborn
(p = 0.002) or yearlings (p = 0.008). The pro-apoptotic genes
caspase 3 (CASP3) and caspase 8 (CASP8) were up-regulated in
BM-MSCs from older horses (p ≤ 0.003).
DISCUSSION
Results from the present study show that in vitro proliferation
percentages of plastic-adherent equine BM- and AT-MSCs were
stable through adult ages, but decreased in samples collected
from geriatric donors. These findings support the hypothesis
generally consistent with Alicka et al., who showed a shorter
population doubling time in AT-MSCs from horses below 5
years of age compared to horses above 15 years of age (18).
Additionally, Vidal et al. reported no difference in proliferative
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FIGURE 2 | Fluorescence labeling. Representative images (20× magnification) of EdU-labeled proliferating cell nuclei (Alexa594—red/pink) and all cell nuclei
(DAPI—blue) from equine bone marrow derived mesenchymal stem cells in different age groups.
capacity of BM-MSCs from horses below 5 years of age (16).
Schröck et al. reported a heterogeneous population of equine
BM-MSCs with a decreasing population of cells with maximum
proliferation speed with increasing donor age (20). Schröck’s
study, however, had a limited study population and was not
designed to provide kinetics or thresholds with regards to donor
age. The current study extends our understanding in horses by
analyzing additional age groups, and interestingly shows that
difference in equine BM- and AT-MSC cellular proliferation were
only seen in pair-wise comparisons involving geriatric horses.
No difference in cellular proliferation rates were observed in
MSCs from horses below 18 years of age. This finding is broadly
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FIGURE 3 | Age-dependent changes in cellular proliferation between cell types. Box plots showing the cellular proliferation (%) of equine adipose tissue (AT)- and
bone marrow (BM)-derived mesenchymal stem cells and dermal fibroblasts (DF) from horses in five different age groups (n = 4 horses per age group per cell type)
after 24 h of labeling with 8µM EdU. Cell types within the same age group not labeled with the same letter are significantly different from each other (p < 0.05).
TABLE 3 | Differentially expressed genes related to cellular proliferation as a function of donor age within adipose tissue- and bone marrow derived mesenchymal stem
cells and dermal fibroblasts from horses in five different age groups (n = 4, N = 60) after one-way ANOVA statistical analysis when significance was set to p < 0.05.
Cell type Gene function

























































*All listed genes were significantly affected by donor age within the given cell type.
†AT, adipose tissue; BM, bone marrow; MSC, mesenchymal stem cells; DF, dermal fibroblasts. Red marked genes indicate an up-regulation in gene expression with increasing donor
age. Blue marked genes indicate a down-regulation in gene expression with increasing donor age.
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FIGURE 4 | Concordance by cell type of differentially expressed genes.
Venn-diagram showing the distribution of differentially expressed genes as a
function of donor age between adipose tissue (AT)- and bone marrow
(BM)-derived mesenchymal stem cells (MSC) and dermal fibroblasts (DF) from
horses in five different age groups. The Venn-diagram represents data
reported in Table 3.
consistent with the gene expression data, where the majority of
age-related changes in steady state mRNA levels were seen in
comparisons involving geriatric horses. Decline in proliferative
capacity with increasing donor age is similar to previous reports
in other species (12–15). However, the pair-wise comparisons
from horses stand in contrast with other species where differences
in proliferation were more progressive and reported already
in 8-year-old monkeys (12) and in humans above 40 years of
age (32).
Cellular proliferation of human AT-MSCs have previously
been reported to be less prominently affected by donor age
compared to BM-MSCs (33). This was not observed in the
present study, where equine BM- and AT-MSCs showed
similar cellular proliferation in all age groups and were
equally affected by donor age. Together, this may heighten
the relevance of BM-MSCs for autologous treatments, as they
have shown a higher therapeutic potential for cartilage and
bone injuries (6, 34, 35). On the other hand, less age related
gene expression changes were seen in AT-MSCs with the
selected biomarker panel compared to BM-MSCs or DFs.
It is likely that the cells have other age-related expression
changes outside the selected biomarker panel as the phenotypic
cellular proliferation was equal for AT- and BM-MSCs across
age groups.
Our finding that DFs have generally higher cellular
proliferation compared to BM-and AT-MSCs is supported
by previous studies where DFs have been shown to be highly
sensitive to mitogenic stimuli and readily expand in adherent
monolayer cultures (19). The decrease in cellular proliferation
with increasing donor age for all three cell types is broadly
consistent with a general decline in the proliferative capacity
of equine primary cells isolated from donor horses with
increasing age.
Molecular mechanisms responsible for the observed decrease
in equine cellular proliferation in samples collected from geriatric
donors could potentially include a decrease in growth factors
and their receptors, a decrease in pro-cycling molecules, and/or
an increase in cell cycle arrest genes and apoptotic factors.
Similar to previous studies, our data demonstrated that the tumor
suppressor genes p53, p21 and p16 were up-regulated in MSCs
from old donors (12, 14, 18). p16 and p21 inhibit DNA replication
by inhibiting cyclin dependent kinases and are considered
markers of senescence (36). p53 is a transcription factor for p21
and can induce transcription of apoptosis-associated genes like
BAX, which leads to activation of CASP3, another apoptotic
factor (37). Interestingly, increased p53 expression in old AT-
MSCs did not result in detectable up-regulation of p21 or
BAX in the geriatric AT-MSCs, which might be due to a lack
of phosphorylation of p53 and a resulting rapid degradation.
An increase in the apoptotic pro-factor CASP8 can also cause
up-regulation of CASP3 (37), possibly explaining why both
CASP8 and CASP3 were up-regulated in BM-MSCs from
geriatric horses.
Taken together, the age related up-regulation of tumor
suppressors and apoptotic factors could explain the lower cellular
proliferation seen in aged horses. This supports a model of
more cells being growth arrested rather than progressing through
the S-phase of the cell cycle and incorporating EdU, which is
consistent with previous studies where increased G1/G0-arrest
and prolonged time in S-phase have been reported in MSCs from
aged donors (12, 18).
GLB1 activity is an additional marker of senescence, with
higher gene expression in senescent cells being reported (38).
In BM-MSCs, an age related increase in GLB1 expression was
seen in geriatric horses corresponding well with previous studies
showing accelerated cellular senescence with increasing donor
age (15, 18).
Interestingly, multiple growth factors actually displayed
higher steady state mRNA levels in BM-MSCs from geriatric
horses. Age-dependent growth factor results are variable in
previous rodent studies (13, 39, 40), but the current data
suggests that the decreased proliferation observed in BM-
MSCs from geriatric horses may be more due to an up-
regulation in tumor-suppressors and apoptotic factors than a
decrease in growth factors or pro-cycling factors. It is moreover
possible that aged BM-MSCs are less responsive to secreted
growth factors, consistent with studies investigating relationships
between growth factor activity and inflammation in aging (41).
Potential age-dependent differences in cellular differentiation
potential, as well as production of paracrine factors to influence
the patient’s immune response or endogenous progenitor
cells relevant to cell-therapy application in horses were not
investigated in the current experiments, but will be important
parameters to assess in future studies. Another parameter not
addressed was potential gender differences in the proliferation of
equine MSCs as a function of age.
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FIGURE 5 | Relative levels of steady state mRNA for targeted gene loci. Heatmap showing the Ln(RQ) levels of gene expression by color change between average
levels in bone marrow (BM)- and adipose tissue (AT)-derived mesenchymal stem cells (MSCs) and dermal fibroblasts (DF) from horses in five different age groups (n =
4 horses per age group per cell type) when grown in T75 cm2 culture flasks with normal expansion medium containing DMEM, 10% FBS, and 1% P/S and harvested
at approximately 80% confluence. Gray boxes indicate no detection of gene expression. N, newborn; Y, yearling; A, adult; M, middle-aged; G, geriatric.
Primary cells were collected from female and male horses
in each age group, but not with even distribution (Table 1). A
relevant study in mice comparing in vitro MSC proliferation as
a function of gender did not observe any differences (42). All
donor horses in the study were in apparent good health for their
age with a few exceptions in older animals (Table 1). Certain
systemic health parameters could affect cell biology parameters
including proliferation. The impact of specific systemic illnesses
on MSCs, as in the case of the 25-year-old lymphoma horse in
the current sample set, will require additional research. Primary
cell lines in the different age groups did consist of both paired
and non-paired samples. Ideally, the study would have been
conducted solely with paired samples as inter-animal variation
is an important consideration (43). To control for this factor, the
data were treated statistically as non-paired and horse number
was added to the statistical models.
Evidence for trilineage differentiation potential is apparent
in equine BM- and AT-MSCs isolated using the techniques
applied in this study (data not shown). Unfortunately, uniform
parameters to validate “stemness” of equine MSCs with
cell surface molecular markers has not been established
(44) and relevant antibodies for equine cell isolates remain
limited (45–47).
In conclusion, all cells independent of age group were able to
be expanded to passage 4, but the proliferation of plastic adherent
equine BM- and AT-MSCs declined significantly in the geriatric
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FIGURE 6 | Age- and cell type-dependent p16 and p21 differences. Bar plots showing mean relative gene expression (RQ) of p16 and p21 steady state mRNA in
monolayer cultures of bone marrow (BM)- and adipose tissue (AT)-derived mesenchymal stem cells (MSC) and dermal fibroblasts (DF) from horses in five different age
groups (n = 4, N = 60) relative to the positive control. *Indicates significant difference between geriatric and newborn age group for BM-MSCs (p < 0.05). N, newborn
(black); Y, yearling (gray); A, adult (green); M, middle-aged (blue); G: geriatric (red).
age group. High in vitro cellular proliferation was seen in BM-
and AT-MSCs from horses below 18 years of age. The cellular
proliferation of BM- and AT-MSCs was similar in all age groups
and they were equally affected by donor age. Underlying gene
expression changes related to proliferation and aging showed a
primary up-regulation in tumor suppressors, apoptotic genes,
and multiple growth factors in MSCs from old horses, and a
down-regulation of some pro-cycling genes depending on cell
type. MSC differentiation potential, as well as the capacity to
mediate inflammatory processes and other paracrine functions
will be important parameters to consider with further research
on donor age as a variable in cell-based therapies for horses.
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